William Bell
Psychiatry · Franklin, TNNPI 1902835358
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 568 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,989, 2.2 times the $909 reported in 2019. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 568 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$887
- Neurocrine Biosciences, Inc.$863
- Johnson & Johnson$855
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$797
- Otsuka America Pharmaceutical, Inc.$633
- plus $5K from 26 others
What the payments were for
- Food & beverage$10,19199%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 95 | $1,243 |
| Teva Pharmaceuticals USA, Inc. | 54 | $887 |
| Neurocrine Biosciences, Inc. | 43 | $863 |
| Johnson & Johnson | 24 | $855 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $797 |
| Otsuka America Pharmaceutical, Inc. | 38 | $633 |
| Neos Therapeutics, LP | 46 | $633 |
| Axsome Therapeutics, Inc. | 21 | $539 |
| Lundbeck LLC | 23 | $495 |
| Sunovion Pharmaceuticals Inc. | 34 | $489 |
| Alkermes, Inc. | 25 | $479 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $431 |
| Ironshore Pharmaceuticals Inc. | 18 | $326 |
| Noven Therapeutics, LLC | 10 | $200 |
| Corium, LLC | 16 | $199 |
| Vanda Pharmaceuticals Inc. | 6 | $164 |
| Supernus Pharmaceuticals, Inc. | 7 | $154 |
| Tris Pharma Inc | 7 | $123 |
| Jazz Pharmaceuticals Inc. | 6 | $121 |
| Harmony Biosciences LLC | 3 | $101 |
| Adlon Therapeutics L.p. | 5 | $93 |
| Eisai Inc. | 5 | $82 |
| Idorsia Pharmaceuticals US Inc | 5 | $82 |
| Vertical Pharmaceuticals, LLC | 3 | $59 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Bausch Health US, LLC | 3 | $51 |
| Abbott | 1 | $34 |
| Merck | 2 | $30 |
| Shire North American Group Inc | 1 | $20 |
| Rhodes Pharmaceuticals L.p. | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,282 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 35 | $47,337 |
| Invega SustennaPaliperidone Palmitate | 12 | $20,043 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $12,585 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 118 | $6,432 |
| Duloxetine Hcl | 91 | $3,409 |
| Aripiprazole | 54 | $2,744 |
| Bupropion XlBupropion Hcl | 27 | $2,640 |
| Quetiapine Fumarate | 76 | $1,645 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 17 | $1,498 |
| Lurasidone Hcl | 12 | $1,416 |
| Alprazolam | 174 | $1,264 |
| Methylphenidate Hcl | 31 | $1,138 |
| Escitalopram Oxalate | 65 | $1,066 |
| Bupropion Hcl SrBupropion Hcl | 55 | $1,040 |
| Lamotrigine | 78 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,243 | $47,33735 claims |
| Johnson & JohnsonInvega Sustenna | $855 | $20,04312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $431 | $12,58524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Franklin
- Sricharan MoturiFranklin$82K
- James HartFranklin$53K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Michelle CochranNashville$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.